Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Alimera Sciences Inc is a drug manufacturers-specialty & generic business based in the US. Alimera Sciences shares (ALIM) are listed on the NASDAQ and all prices are listed in US Dollars. Alimera Sciences employs 130 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Long-term investors
Our top pick for
Beginners
Our top pick for
Active traders
| Latest market close | $4.55 |
|---|---|
| 52-week range | $3.94 - $12.25 |
| 50-day moving average | $5.13 |
| 200-day moving average | $7.08 |
| Wall St. target price | $14.83 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-0.20 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $4.55 from 2022-01-20
| 1 week (2022-01-13) | -3.19% |
|---|---|
| 1 month (2021-12-18) | N/A |
| 3 months (2021-10-18) | N/A |
| 6 months (2021-07-22) | -49.89% |
| 1 year (2021-01-22) | -43.13% |
|---|---|
| 2 years (2020-01-22) | -38.18% |
| 3 years (2019-01-22) | 441.41% |
| 5 years (2017-01-20) | 285.59% |
Valuing Alimera Sciences stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Alimera Sciences's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Alimera Sciences's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $4.9 million.
The EBITDA is a measure of a Alimera Sciences's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $58.8 million |
|---|---|
| Operating margin TTM | 3.95% |
| Gross profit TTM | $43.9 million |
| Return on assets TTM | 2.66% |
| Return on equity TTM | 0% |
| Profit margin | -2.11% |
| Book value | $-0.48 |
| Market capitalisation | $31.3 million |
TTM: trailing 12 months
We're not expecting Alimera Sciences to pay a dividend over the next 12 months.
Alimera Sciences's shares were split on a 1:15 basis on 14 November 2019. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Alimera Sciences shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Alimera Sciences shares which in turn could have impacted Alimera Sciences's share price.
Over the last 12 months, Alimera Sciences's shares have ranged in value from as little as $3.94 up to $12.25. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Alimera Sciences's is 1.6325. This would suggest that Alimera Sciences's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Alimera Sciences, Inc. , a pharmaceutical company, engages in the development and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. The company sells its products to physician offices, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. The company was incorporated in 2003 and is headquartered in Alpharetta, Georgia.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Starting Jan. 18, every household can order up to four free at-home COVID-19 tests. But you’ll have to wait for them.
While there are no known plans to expand the acceptance of Doge to its cars, customers can already buy a Tesla with Bitcoin.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Donut earns up to 10% APY, but you must have an iOS device.
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
Record vehicle deliveries cause the Tesla stock price to move close to all-time highs.